LOGIN
ID
PW
MemberShip
2025-05-04 09:41
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Lee Hyun-ju named as the representative of ZP Therapeutics
by
Eo, Yun-Ho
Nov 14, 2024 05:52am
Lee Hyun-ju (48), ex-Daiichi Sankyo Korea's Oncology Business Franchise Head, was appointed as the new representative of ZP Therapeutics Korea. Industry sources said Zuellig Pharma has recruited Lee Hyun-ju as the new head of ZP Therapeutics Korea, Zuellig Pharma's commercial services corporation. Lee holds a degree from Sungkyunkwan
Company
Celltrion anticipates Trump admin will bring positive shift
by
Whang, byung-woo
Nov 14, 2024 05:51am
Celltrion anticipates that President-elect Donald Trump's second administration in the United States will positively affect the company's biosimilars and Contract Development and Management Operations (CDMO) services. On November 12, Celltrion presented stockholders with the potential impact on the business under the title 'The Business Im
Company
¡®Access to bispecific antibody Columvi should be improved¡¯
by
Son, Hyung Min
Nov 14, 2024 05:51am
¡°Diffuse large B-cell lymphoma (DLBCL) is a disease in which one in four patients experience relapse even after treatment. The bispecific antibody Columvi has demonstrated efficacy in relapsed patients at up to 18 months of follow-up. The clinical performance of Columvi is not just an incremental improvement over existing therapies, but a p
InterView
'Early detection of RA can help prevent severe symptoms'
by
Whang, byung-woo
Nov 14, 2024 05:51am
"Rheumatoid arthritis not only induces permanent joint deformities and damages but also has a detrimental effect on quality of life due to many general symptoms. As effective disease management becomes possible following the recent introduction of various treatment options, early diagnosis and patient-customized treatment approach are crucial."
Company
Global CDMOs compete to expand ADC capacities
by
Kim, Jin-Gu
Nov 14, 2024 05:51am
Global competition is heating up in the contract development manufacturing organization (CDMO) market for antibody-drug conjugates (ADCs). Major players include Switzerland's Lonza and Samsung Biologics, the world's top two CDMOs, which are competitively expanding their manufacturing facilities. Lonza recently announced the expansion of a
Product
MOHW cautions non-face-to-face Wegovy prescriptions
by
Kang Hye-Kyung
Nov 13, 2024 05:55am
The government has asked medical institutions for cooperation in making indiscriminate Wegovy prescriptions. The Ministry of Health and Welfare said on the 11th through the medical community, ¡°Regarding Wegovy, which was recently released as a treatment for obesity, medical institutions are issuing prescriptions without sufficiently e
Opinion
[Reporter's View] voluntary resignation with compensation
by
Lee, Seok-Jun
Nov 13, 2024 05:54am
As the year-end is nearing, several pharmaceutical companies are considering restructuring. Rumor has it that these companies may have plans for reducing OTC businesses and laying off staff who are age 55 or older. It remains uncertain whether it is a rumor or an actual plan, but restructuring could be possible. Over five pharmaceutical comp
Company
Imfinzi combo drug Imjudo can be prescribed at hospitals
by
Eo, Yun-Ho
Nov 13, 2024 05:54am
Immuno-oncology drug Imfinzi's combination partner Imjudo may now be prescribed in general hospitals in Korea. According to industry sources, AstraZeneca Korea's CTLA-4 inhibitor Imjudo (tremelimumab) has passed the drug committees (DCs) of tertiary hospitals in Korea including Seoul National University Hospital and Seoul Asan Medical Cen
Company
Treatment-refractory Dravet syndrome calls for new options
by
Whang, byung-woo
Nov 13, 2024 05:54am
Despite increased treatment options for the ultra-rare Dravet syndrome, there are still gaps in care that require attention. Even with the introduction of medical cannabis, cannabidiol, there are patients who do not respond to the drug, which is why improving access to new options should be considered. Dravet syndrome is a rare neuro
Company
'Choline alfoscerate' prescription market continues to grow
by
Chon, Seung-Hyun
Nov 13, 2024 05:54am
The cognitive enhancer 'choline alfoscerate (choline products)' has expanded its presence in the prescription market. Choline products' growth slowed earlier this year but rebounded in Q3, further expanding the market size. Although a few companies withdrew from the market due to the risk of failing clinical re-evaluation, the prescription marke
<
51
52
53
54
55
56
57
58
59
60
>